Cargando…
Systemic network analysis identifies XIAP and IκBα as potential drug targets in TRAIL resistant BRAF mutated melanoma
Metastatic melanoma remains a life-threatening disease because most tumors develop resistance to targeted kinase inhibitors thereby regaining tumorigenic capacity. We show the 2nd generation hexavalent TRAIL receptor-targeted agonist IZI1551 to induce pronounced apoptotic cell death in mutBRAF melan...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6218484/ https://www.ncbi.nlm.nih.gov/pubmed/30416750 http://dx.doi.org/10.1038/s41540-018-0075-y |
_version_ | 1783368460360744960 |
---|---|
author | Del Mistro, Greta Lucarelli, Philippe Müller, Ines De Landtsheer, Sébastien Zinoveva, Anna Hutt, Meike Siegemund, Martin Kontermann, Roland E. Beissert, Stefan Sauter, Thomas Kulms, Dagmar |
author_facet | Del Mistro, Greta Lucarelli, Philippe Müller, Ines De Landtsheer, Sébastien Zinoveva, Anna Hutt, Meike Siegemund, Martin Kontermann, Roland E. Beissert, Stefan Sauter, Thomas Kulms, Dagmar |
author_sort | Del Mistro, Greta |
collection | PubMed |
description | Metastatic melanoma remains a life-threatening disease because most tumors develop resistance to targeted kinase inhibitors thereby regaining tumorigenic capacity. We show the 2nd generation hexavalent TRAIL receptor-targeted agonist IZI1551 to induce pronounced apoptotic cell death in mutBRAF melanoma cells. Aiming to identify molecular changes that may confer IZI1551 resistance we combined Dynamic Bayesian Network modelling with a sophisticated regularization strategy resulting in sparse and context-sensitive networks and show the performance of this strategy in the detection of cell line-specific deregulations of a signalling network. Comparing IZI1551-sensitive to IZI1551-resistant melanoma cells the model accurately and correctly predicted activation of NFκB in concert with upregulation of the anti-apoptotic protein XIAP as the key mediator of IZI1551 resistance. Thus, the incorporation of multiple regularization functions in logical network optimization may provide a promising avenue to assess the effects of drug combinations and to identify responders to selected combination therapies. |
format | Online Article Text |
id | pubmed-6218484 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-62184842018-11-09 Systemic network analysis identifies XIAP and IκBα as potential drug targets in TRAIL resistant BRAF mutated melanoma Del Mistro, Greta Lucarelli, Philippe Müller, Ines De Landtsheer, Sébastien Zinoveva, Anna Hutt, Meike Siegemund, Martin Kontermann, Roland E. Beissert, Stefan Sauter, Thomas Kulms, Dagmar NPJ Syst Biol Appl Article Metastatic melanoma remains a life-threatening disease because most tumors develop resistance to targeted kinase inhibitors thereby regaining tumorigenic capacity. We show the 2nd generation hexavalent TRAIL receptor-targeted agonist IZI1551 to induce pronounced apoptotic cell death in mutBRAF melanoma cells. Aiming to identify molecular changes that may confer IZI1551 resistance we combined Dynamic Bayesian Network modelling with a sophisticated regularization strategy resulting in sparse and context-sensitive networks and show the performance of this strategy in the detection of cell line-specific deregulations of a signalling network. Comparing IZI1551-sensitive to IZI1551-resistant melanoma cells the model accurately and correctly predicted activation of NFκB in concert with upregulation of the anti-apoptotic protein XIAP as the key mediator of IZI1551 resistance. Thus, the incorporation of multiple regularization functions in logical network optimization may provide a promising avenue to assess the effects of drug combinations and to identify responders to selected combination therapies. Nature Publishing Group UK 2018-11-05 /pmc/articles/PMC6218484/ /pubmed/30416750 http://dx.doi.org/10.1038/s41540-018-0075-y Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Del Mistro, Greta Lucarelli, Philippe Müller, Ines De Landtsheer, Sébastien Zinoveva, Anna Hutt, Meike Siegemund, Martin Kontermann, Roland E. Beissert, Stefan Sauter, Thomas Kulms, Dagmar Systemic network analysis identifies XIAP and IκBα as potential drug targets in TRAIL resistant BRAF mutated melanoma |
title | Systemic network analysis identifies XIAP and IκBα as potential drug targets in TRAIL resistant BRAF mutated melanoma |
title_full | Systemic network analysis identifies XIAP and IκBα as potential drug targets in TRAIL resistant BRAF mutated melanoma |
title_fullStr | Systemic network analysis identifies XIAP and IκBα as potential drug targets in TRAIL resistant BRAF mutated melanoma |
title_full_unstemmed | Systemic network analysis identifies XIAP and IκBα as potential drug targets in TRAIL resistant BRAF mutated melanoma |
title_short | Systemic network analysis identifies XIAP and IκBα as potential drug targets in TRAIL resistant BRAF mutated melanoma |
title_sort | systemic network analysis identifies xiap and iκbα as potential drug targets in trail resistant braf mutated melanoma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6218484/ https://www.ncbi.nlm.nih.gov/pubmed/30416750 http://dx.doi.org/10.1038/s41540-018-0075-y |
work_keys_str_mv | AT delmistrogreta systemicnetworkanalysisidentifiesxiapandikbaaspotentialdrugtargetsintrailresistantbrafmutatedmelanoma AT lucarelliphilippe systemicnetworkanalysisidentifiesxiapandikbaaspotentialdrugtargetsintrailresistantbrafmutatedmelanoma AT mullerines systemicnetworkanalysisidentifiesxiapandikbaaspotentialdrugtargetsintrailresistantbrafmutatedmelanoma AT delandtsheersebastien systemicnetworkanalysisidentifiesxiapandikbaaspotentialdrugtargetsintrailresistantbrafmutatedmelanoma AT zinovevaanna systemicnetworkanalysisidentifiesxiapandikbaaspotentialdrugtargetsintrailresistantbrafmutatedmelanoma AT huttmeike systemicnetworkanalysisidentifiesxiapandikbaaspotentialdrugtargetsintrailresistantbrafmutatedmelanoma AT siegemundmartin systemicnetworkanalysisidentifiesxiapandikbaaspotentialdrugtargetsintrailresistantbrafmutatedmelanoma AT kontermannrolande systemicnetworkanalysisidentifiesxiapandikbaaspotentialdrugtargetsintrailresistantbrafmutatedmelanoma AT beissertstefan systemicnetworkanalysisidentifiesxiapandikbaaspotentialdrugtargetsintrailresistantbrafmutatedmelanoma AT sauterthomas systemicnetworkanalysisidentifiesxiapandikbaaspotentialdrugtargetsintrailresistantbrafmutatedmelanoma AT kulmsdagmar systemicnetworkanalysisidentifiesxiapandikbaaspotentialdrugtargetsintrailresistantbrafmutatedmelanoma |